Patents by Inventor Daria Mochly-Rosen

Daria Mochly-Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal structure of aldehyde dehydrogenase and methods of use thereof
    Patent number: 8124389
    Abstract: The present disclosure provides a crystal structure of aldehyde dehydrogenase (ALDH) with a modulator of ALDH bound thereto. The present disclosure provides a computer readable medium comprising atomic coordinates for an ALDH polypeptide and a modulator bound to a site within the polypeptide. A method is also provided. In general terms, the method comprises computationally identifying a compound that binds to an ALDH polypeptide, using the atomic coordinates.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: February 28, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Indiana University Research and Technology Corporation
    Inventors: Che-Hong Chen, Daria Mochly-Rosen, Thomas D. Hurley
  • Crystal Structure of Aldehyde Dehydrogenase and Methods of Use Thereof
    Publication number: 20120028287
    Abstract: The present disclosure provides a crystal structure of aldehyde dehydrogenase (ALDH) with a modulator of ALDH bound thereto. The present disclosure provides a computer readable medium comprising atomic coordinates for an ALDH polypeptide and a modulator bound to a site within the polypeptide. A method is also provided. In general terms, the method comprises computationally identifying a compound that binds to an ALDH polypeptide, using the atomic coordinates.
    Type: Application
    Filed: October 10, 2011
    Publication date: February 2, 2012
    Inventors: Che-Hong CHEN, Daria MOCHLY-ROSEN, Thomas D. HURLEY
  • Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
    Publication number: 20120010248
    Abstract: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.
    Type: Application
    Filed: August 22, 2011
    Publication date: January 12, 2012
    Inventors: Daria Mochly-Rosen, Che-Hong Chen, Xiaohu Ouyang
  • PEPTIDE INHIBITORS OF PROTEIN KINASE C
    Publication number: 20110275575
    Abstract: PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Applicant: Board of Trustees of the Leland Stanford Junior University
    Inventor: Daria Mochly-Rosen
  • Isozyme-specific antagonists of protein kinase C
    Patent number: 7994133
    Abstract: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of ?PKC are also disclosed.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: August 9, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Daria Mochly-Rosen
  • ??RACK peptide composition and method for protection against tissue damage due to ischemia
    Patent number: 7985726
    Abstract: A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ??RACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: July 26, 2011
    Assignee: The Board of Trustees of the Leland Standford Junior University
    Inventor: Daria Mochly-Rosen
  • Peptides for Activation and Inhibition of Delta-PKC
    Publication number: 20110143991
    Abstract: Peptides able to inhibit or activate the translocation or function of ?PKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for ?PKC-selective agonists and antagonists.
    Type: Application
    Filed: November 30, 2010
    Publication date: June 16, 2011
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daria Mochly-Rosen, Leon E. Chen
  • Peptide inhibitors of protein kinase C
    Patent number: 7939493
    Abstract: PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: May 10, 2011
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventor: Daria Mochly-Rosen
  • Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
    Publication number: 20110105602
    Abstract: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.
    Type: Application
    Filed: March 7, 2008
    Publication date: May 5, 2011
    Inventors: DARIA MOCHLY-ROSEN, Che-Hong Chen, Xiaohu Ouyang
  • Method for reducing central nervous system tissue or cell damage in a subject due to stroke
    Patent number: 7915219
    Abstract: Peptides able to inhibit or activate the translocation or function of ?PKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for ?PKC-selective agonists and antagonists.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: March 29, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daria Mochly-Rosen, Leon E. Chen
  • PROTEIN KINASE C PEPTIDES FOR USE IN WITHDRAWAL
    Publication number: 20110009331
    Abstract: A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ? and/or ? isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for ?PKC or ?PKC and instructions for use.
    Type: Application
    Filed: September 10, 2010
    Publication date: January 13, 2011
    Inventors: Daria Mochly-Rosen, Joan J. Kendig, Sarah M. Sweitzer
  • Peptides for activation and inhibition of ?PKC
    Patent number: 7851586
    Abstract: Peptides able to inhibit or activate the translocation or function of ?PKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for ?PKC-selective agonists and antagonists.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: December 14, 2010
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daria Mochly-Rosen, Leon E. Chen
  • ISOZYME-SPECIFIC ANTAGONISTS OF PROTEIN KINASE C
    Publication number: 20100311644
    Abstract: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of ?PKC are also disclosed.
    Type: Application
    Filed: May 24, 2010
    Publication date: December 9, 2010
    Inventor: Daria Mochly-Rosen
  • Peptide inhibitors of protein kinase C
    Patent number: 7833984
    Abstract: PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: November 16, 2010
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Daria Mochly-Rosen
  • Protein kinase C peptides for use in withdrawal
    Patent number: 7803775
    Abstract: A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ? and/or ? isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for ?PKC or ?PKC and instructions for use.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: September 28, 2010
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daria Mochly-Rosen, Joan J. Kendig, Sarah M. Sweitzer
  • Isozyme-specific antagonists of protein kinase C
    Patent number: 7745412
    Abstract: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of ?PKC are also disclosed.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: June 29, 2010
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Daria Mochly-Rosen
  • Peptides for activation and inhibition of ?PKC
    Patent number: 7745388
    Abstract: Peptides able to inhibit or activate the translocation or function of ?PKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for ?PKC-selective agonists and antagonists.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: June 29, 2010
    Assignees: National Institute of Health (NIH), The United States of America as represented by the Department of Health and Human Services, The United States of America as represented by NIH Division of Extramural Inventions and Technology Resources (DEITR)
    Inventors: Daria Mochly-Rosen, Leon E. Chen
  • Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof
    Publication number: 20100113423
    Abstract: The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.
    Type: Application
    Filed: October 19, 2009
    Publication date: May 6, 2010
    Inventors: Daria Mochly-Rosen, Che-Hong Chen, Wenjin Yang
  • MODULATORS OF ALDEHYDE DEHYDROGENASE ACTIVITY AND METHODS OF USE THEREOF
    Publication number: 20100063100
    Abstract: The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.
    Type: Application
    Filed: September 3, 2009
    Publication date: March 11, 2010
    Inventors: CHE-HONG CHEN, Daria Mochly-Rosen, Wenjin Yang
  • COMPOSITIONS AND METHODS FOR MODULATING EPSILON PROTEIN KINASE C-MEDIATED CYTOPROTECTION
    Publication number: 20100048482
    Abstract: Compositions and methods for reducing ischemic cell damage and treating mitochondrial disorders using therapeutic agents derived from the V2 domain of epsilon protein kinase C (PKC) are described.
    Type: Application
    Filed: August 17, 2009
    Publication date: February 25, 2010
    Applicant: Board of Trustees of the Leland Stanford Junior University
    Inventors: Daria Mochly-Rosen, Grant R. Budas